Rakuten Investment Management Inc. Purchases New Shares in Gilead Sciences, Inc. $GILD

Rakuten Investment Management Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 65,400 shares of the biopharmaceutical company’s stock, valued at approximately $7,259,000.

A number of other institutional investors also recently modified their holdings of GILD. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the third quarter worth $26,000. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences during the 2nd quarter worth $27,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences during the second quarter worth about $30,000. Finally, Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $131.14 on Friday. Gilead Sciences, Inc. has a 52-week low of $92.21 and a 52-week high of $133.10. The company has a market cap of $162.70 billion, a P/E ratio of 20.33, a P/E/G ratio of 0.68 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock’s 50-day simple moving average is $123.76 and its 200 day simple moving average is $118.46.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares in the company, valued at approximately $18,709,027.93. This trade represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00. Following the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at $70,740,911.34. The trade was a 1.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 141,757 shares of company stock valued at $17,569,112. 0.27% of the stock is owned by corporate insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: NEJM published full Phase 3 ASCENT‑04/KEYNOTE‑D19 results showing Trodelvy (sacituzumab govitecan) + Keytruda met the primary endpoint with a ~35% PFS improvement (HR 0.65), supporting the combo as a potential new first‑line standard in PD‑L1+ metastatic TNBC — a major commercial catalyst for Gilead’s oncology franchise. NEJM ASCENT-04 Results
• Positive Sentiment: Multiple outlets (PharmaLetter) summarized the NEJM publication and reinforced the significance of the clinical data for Trodelvy’s uptake and reimbursement discussions — amplifying the immediate market reaction. PharmaLetter Trodelvy-Keytruda NEJM Coverage
• Positive Sentiment: Rothschild & Co Redburn raised its price target to $159 and kept a “buy” rating — a bullish institutional signal that supports further upside and likely contributed to buying momentum. Rothschild & Co Redburn Price Target
• Positive Sentiment: Investor commentary highlighting margin expansion and stronger free cash flow as underappreciated drivers has supported fundamental buying beyond the clinical news. Seeking Alpha on Margins & Cash Flow
• Neutral Sentiment: Market write‑ups and a Zacks note pointed out that GILD outpaced the broader market today — useful for context but largely descriptive of price action rather than new fundamental change. Zacks: Why GILD Outpaced Market
• Neutral Sentiment: Valuation and technical pieces note recent share‑price strength and improved momentum — these can attract traders but don’t alter the clinical/commercial thesis. Yahoo Valuation Check
• Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at ~$123.50), reducing his stake by ~36% — an insider sale that can prompt short‑term investor concern about timing or confidence (though insiders sell for many non‑signal reasons). SEC Form 4 — Bluestone
• Negative Sentiment: RBC’s price target (~$103, sector perform) remains well below current levels — a conservative analyst view that could limit upside if other firms adopt similar stances. RBC Price Target Note

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. HSBC increased their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Truist Financial began coverage on Gilead Sciences in a research note on Monday, November 24th. They issued a “buy” rating and a $140.00 price target on the stock. Citigroup boosted their price target on Gilead Sciences from $135.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Wells Fargo & Company increased their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Finally, Royal Bank Of Canada lifted their target price on Gilead Sciences from $100.00 to $103.00 and gave the company a “sector perform” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $133.52.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.